TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00003531
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00338130
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid or Capsule
Study: NCT00251316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
Study: NCT00346164
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01144403
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: as prescribed, 6 cycles
Study: NCT00537199
Drug: OraTest
Normalized name: testosterone enanthate Injectable Solution [Duratest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
Study: NCT02266849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets daily for three days
Study: NCT02624167
Drug: NW-3509A
Normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
Study: NCT02624167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given oral dose of matching Placebo
Study: NCT01332786
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest
Study: NCT01443689
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given conventional therapy only.
Study: NCT03187496
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive caffeine on Days 1 and 12.
Study: NCT03187496
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each subject will receive rosuvastatin on Days 2 and 13.
Study: NCT02170831
Drug: BIBR 1048 MS placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03166124
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01177163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
Study: NCT01177163
Drug: JNJ 28431754 300 mg/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
Study: NCT01177163
Drug: JNJ 28431754 100 mg/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
Study: NCT03291041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT00739973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02498535
Drug: Nitric Oxide 160 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric Oxide 160 ppm
Study: NCT02105155
Drug: Conversion at day 7 ± 3 Prograf® to Advagraf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
Study: NCT02105155
Drug: Conversion at day 90±5 Prograf® to Advagraf®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
Study: NCT02244073
Drug: Human insulin - Insulin administration to control blood glucose level.
Approvals — FDA: no, EMA: no, PMDA: no
Description: On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
Study: NCT03492658
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
Study: NCT00339872
Drug: IMA-638
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02198924
Drug: Parecoxib and Celecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
Study: NCT02198924
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control patients are supplied with the corresponding placebo with the same instructions.
Study: NCT02130778
Drug: Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
Study: NCT02858726
Drug: CR845 0.5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV medication delivered three times/week
Study: NCT02858726
Drug: CR845 1 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV medication delivered three times/week
Study: NCT02858726
Drug: CR845 1.5mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV medication delivered three times/week
Study: NCT02858726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV medication delivered three times/week
Study: NCT01551147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
Study: NCT01392326
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00190879
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00233987
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/kg IV 2 days before transplant.
Study: NCT03955939
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to label instructions.
Study: NCT00824369
Drug: No drug will be administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug will be administered.
Study: NCT02614963
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irritable bowel syndrome patients treated with placebo
Study: NCT02188082
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00813826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, TID
Study: NCT01007279
Drug: ROSUVASTATIN
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg before procedure
Study: NCT02408445
Drug: testosterone cypionate 200mg/ml
Normalized name: TESTOSTERONE CYPIONATE 200MG/ML INJ (IN OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
Study: NCT00984516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Placebo, 100μl administered once prior to wounding
Study: NCT00984516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
Study: NCT03707041
Drug: P218 (1000 mg) Oral Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg P218 (4 x 250 mg capsules)
Study: NCT03707041
Drug: Placebo Oral Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matched to the P218 capsules with regard to appearance and taste
Study: NCT01465282
Drug: CT327 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% CT327 (w/w) ointment
Study: NCT01465282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03136406
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03136406
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03136406
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT02644161
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
Study: NCT03404401
Drug: BLI4700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bowel preparation
Study: NCT00988208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo once each day on Days 1-14 of the treatment cycle
Study: NCT01796964
Drug: ESBA1008 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: For intravitreal (IVT) injection
Study: NCT01757899
Drug: Methylprednisolone Arm
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
Study: NCT01757899
Drug: Sterile Saline Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
Study: NCT01546922
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
Study: NCT03170388
Drug: IDP-126 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: NCT03170388
Drug: IDP-126 Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel
Study: NCT02000531
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
Study: NCT02956616
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
Study: NCT02227459
Drug: ND-L02-s0201 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00856505
Drug: Everolimus and mycophenolate sodium
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
Study: NCT03778723
Drug: Total intravenous anesthesia (TIVA)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
Study: NCT03778723
Drug: Inhalation Anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane at a concentration of 2-2.5%
Study: NCT03778723
Drug: Rescue fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
Study: NCT02650141
Drug: ziyinxiehuo Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper
Study: NCT02650141
Drug: zishenqinggan Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper
Study: NCT03353298
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tablets given to participants once daily for 9 months
Study: NCT02274948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
Study: NCT00031031
Drug: Kanglaite Injection (KLT)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01668121
Drug: Symbicort Turbohaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00010413
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02775539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00314782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03427476
Drug: CTT1057
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging.
Study: NCT02640365
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: unresectable metastatic colorectal cancer
Study: NCT02640365
Drug: 5-fluorouracile (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: unresectable metastatic colorectal cancer
Study: NCT01975194
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
Study: NCT03768349
Drug: Ga-68 PSMA11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga-68 PSMA11 PET/CT for detection of tumor location
Study: NCT03768349
Drug: F-18 PSMA 1007
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-18 PSMA 1007 PET/CT for detection of tumor location
Study: NCT05487560
Drug: Esomezol Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomezol Cap, Once daily administered per the locally approved product information
Study: NCT00003430
Drug: L-778,123
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03417830
Drug: GSK2398852 (unlabeled anti-SAP mAb)
Normalized name: HURA CREPITANS SAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
Study: NCT03417830
Drug: 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)
Normalized name: HURA CREPITANS SAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
Study: NCT00467987
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04526652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluating anxiety score in both arms
Study: NCT03295214
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen given for pain relief
Study: NCT01825837
Drug: BIA 2-093 300 mg once daily [Group 3 (Part II)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
Study: NCT01825837
Drug: BIA 2-093 900 mg (Part I)
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
Study: NCT02959476
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive comparator
Study: NCT00941720
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
Study: NCT04309526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00190580
Drug: Conventional antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
Study: NCT05299567
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo with the same color and size than azithromycin tree days a wek for 6 months
Study: NCT00171340
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
Study: NCT02739204
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
Study: NCT01879332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets for oral administration
Study: NCT01685658
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
Study: NCT01685658
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
Study: NCT03020784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03990974
Drug: postoperative antimicrobial prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
Study: NCT00554723
Drug: NeuroAid matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
Study: NCT05123781
Drug: Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of the Reference product was administered orally with 240 ml of water
Study: NCT00688402
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00627081
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage
Study: NCT00810888
Drug: recombinant activated factor VII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
Study: NCT00810888
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)